12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Company News  |  Other News

Shire, TWi Pharmaceuticals, Par Pharmaceutical neurology news

Shire, TWi and Par Pharmaceutical's Anchen Pharmaceuticals Inc. subsidiary settled a patent infringement suit related to an ANDA submitted by TWi for a generic version of Shire's ADHD drug Intuniv guanfacine extended release. Under the settlement, Anchen will receive a license to market the drug on July 1, 2016, while TWi, Anchen's authorized distributor and filing agent,...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >